The researchers specifically proposed that combining Rova-T with anti-PD(L)1 could be advantageous for patients by activating multiple pathways synergistically, thus enhancing the effects of immune system targeting and directly attacking SCLC tumor cells that express DLL3. Here, CD274 is linked to neoplasm.